NYSEAMERICAN:MYO Myomo (MYO) Stock Price, News & Analysis → My system predicted the BA collapse – now it’s issuing an AI warning (From Chaikin Analytics) (Ad) Free MYO Stock Alerts $3.58 -0.06 (-1.65%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$3.50▼$3.7050-Day Range N/A52-Week Range$0.37▼$5.58Volume127,646 shsAverage Volume354,446 shsMarket Capitalization$103.18 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Myomo alerts: Email Address Myomo MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside81.6% Upside$6.50 Price TargetShort InterestHealthy2.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 14 Articles This WeekInsider TradingAcquiring Shares$175,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.18) to ($0.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.11 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMyomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMyomo has only been the subject of 1 research reports in the past 90 days.Read more about Myomo's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.85% of the float of Myomo has been sold short.Short Interest Ratio / Days to CoverMyomo has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Myomo has recently decreased by 6.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyomo does not currently pay a dividend.Dividend GrowthMyomo does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MYO. Previous Next 1.8 News and Social Media Coverage News SentimentMyomo has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Myomo this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myomo insiders have bought more of their company's stock than they have sold. Specifically, they have bought $175,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Myomo is held by insiders.Percentage Held by Institutions44.99% of the stock of Myomo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myomo's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myomo are expected to grow in the coming year, from ($0.18) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myomo is -13.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myomo is -13.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyomo has a P/B Ratio of 10.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingLook Who Fired the World’s Richest ManThis company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.Get the full story here. About Myomo Stock (NYSEAMERICAN:MYO)Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More MYO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYO Stock News HeadlinesMay 13 at 5:26 PM | finance.yahoo.comMYO: Myomo is Driving Advancements in Wearable TechnologyMay 13 at 3:34 AM | americanbankingnews.comMyomo, Inc. to Post Q3 2024 Earnings of $0.01 Per Share, HC Wainwright Forecasts (NYSEAMERICAN:MYO)May 12 at 3:50 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Myomo (NYSEAMERICAN:MYO)May 10, 2024 | finance.yahoo.comMyomo Inc (MYO) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amid Financial ...May 10, 2024 | finance.yahoo.comMyomo Inc Reports Q1 2024 Earnings: Revenue Up Despite ChallengesMay 9, 2024 | finance.yahoo.comMyomo, Inc. (AMEX:MYO) Q1 2024 Earnings Call TranscriptMay 8, 2024 | investorplace.comMYO Stock Earnings: Myomo Meets EPS, Misses Revenue for Q1 2024May 8, 2024 | finance.yahoo.comMyomo Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comMyomo is about to announce its earnings — here's what Wall Street expectsMay 6, 2024 | finance.yahoo.comMyomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS FeesMay 2, 2024 | finance.yahoo.comMyomo, Inc. (MYO) Stock Price, News, Quote & History - Yahoo FinanceMay 1, 2024 | businesswire.comMyomo to Report First Quarter Financial Results on May 8, 2024April 20, 2024 | finance.yahoo.comMyomo, Inc. (MYO)March 30, 2024 | investing.comMyomo appoints Heather Getz to board of directorsMarch 28, 2024 | businesswire.comMyomo Appoints Heather Getz to its Board of DirectorsMarch 28, 2024 | businesswire.comMyomo Appoints Heather Getz to its Board of DirectorsMarch 18, 2024 | ca.sports.yahoo.comColby Covington reacts to Jorge Masvidal vs. Nate Diaz boxing match: ‘Sloppy, old f*cking dudes’March 18, 2024 | finance.yahoo.comDirector Thomas Kirk Acquires 50,000 Shares of Myomo Inc (MYO)March 13, 2024 | seekingalpha.comMyomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility AidMarch 10, 2024 | seekingalpha.comMyomo, Inc.: In Motion To Accelerating Revenue GrowthMarch 9, 2024 | seekingalpha.comMyomo, Inc. (MYO) Q4 2023 Earnings Call TranscriptMarch 9, 2024 | markets.businessinsider.comMyomo Inc.: Strong Growth and Regulatory Tailwinds Support Buy RatingMarch 8, 2024 | finance.yahoo.comMyomo, Inc. (AMEX:MYO) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | investorplace.comMYO Stock Earnings: Myomo Misses EPS, Misses Revenue for Q4 2023March 7, 2024 | msn.comMyomo GAAP EPS of -$0.07 misses by $0.01, revenue of $4.76M misses by $0.06MSee More Headlines Receive MYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myomo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNYSEAMERICAN:MYO CUSIPN/A CIK1369290 Webmyomo.com Phone(617) 996-9058FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$6.50 Low Stock Price Target$6.50 Potential Upside/Downside+80.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,150,000.00 Net Margins-47.77% Pretax Margin-46.77% Return on Equity-94.02% Return on Assets-60.79% Debt Debt-to-Equity RatioN/A Current Ratio2.83 Quick Ratio2.40 Sales & Book Value Annual Sales$19.24 million Price / Sales5.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book10.59Miscellaneous Outstanding Shares28,820,000Free Float27,893,000Market Cap$103.75 million OptionableNot Optionable Beta1.51 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Paul R. Gudonis (Age 69)Chairman, President & CEO Comp: $526.56kMr. David A. Henry (Age 63)Chief Financial Officer Comp: $401.56kDr. Harry Kovelman M.D. (Age 65)Chief Medical Officer Comp: $426.03kColin AndersonGlobal Director of OperationsMr. Joseph ChicoskieDirector of MarketingMs. Galina ShtivelmanSenior Director of Human ResourcesMr. Micah J. Mitchell (Age 48)Chief Commercial Officer Comp: $317.39kMore ExecutivesKey CompetitorsCollPlant BiotechnologiesNASDAQ:CLGNEnvoy MedicalNASDAQ:COCHMilestone ScientificNYSE:MLSSVicarious SurgicalNYSE:RBOTUnited Health ProductsOTCMKTS:UEECView All CompetitorsInsiders & InstitutionsHerr Investment Group LLCBought 665,330 shares on 5/14/2024Ownership: 5.711%Vanguard Group Inc.Sold 51,437 shares on 5/10/2024Ownership: 4.049%PFG AdvisorsBought 20,016 shares on 5/7/2024Ownership: 0.162%Essex Investment Management Co. LLCBought 508,249 shares on 5/3/2024Ownership: 2.093%Rosalind Advisors Inc.Bought 527,830 shares on 4/25/2024Ownership: 8.592%View All Insider TransactionsView All Institutional Transactions MYO Stock Analysis - Frequently Asked Questions Should I buy or sell Myomo stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MYO shares. View MYO analyst ratings or view top-rated stocks. What is Myomo's stock price target for 2024? 2 brokers have issued 12 month target prices for Myomo's stock. Their MYO share price targets range from $6.50 to $6.50. On average, they anticipate the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 81.6% from the stock's current price. View analysts price targets for MYO or view top-rated stocks among Wall Street analysts. How have MYO shares performed in 2024? Myomo's stock was trading at $4.74 at the beginning of the year. Since then, MYO stock has decreased by 24.5% and is now trading at $3.58. View the best growth stocks for 2024 here. How were Myomo's earnings last quarter? Myomo, Inc. (NYSEAMERICAN:MYO) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The firm had revenue of $4.76 million for the quarter, compared to analyst estimates of $4.70 million. Myomo had a negative trailing twelve-month return on equity of 94.02% and a negative net margin of 47.77%. What guidance has Myomo issued on next quarter's earnings? Myomo updated its second quarter 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.0 million-, compared to the consensus revenue estimate of $5.1 million. What other stocks do shareholders of Myomo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Genocea Biosciences (GNCA), Agile Therapeutics (AGRX), Sarepta Therapeutics (SRPT), Aclaris Therapeutics (ACRS), Remark (MARK), Synergy Pharmaceuticals (SGYP), VBI Vaccines (VBIV), Athersys (ATHX) and Anavex Life Sciences (AVXL). Who are Myomo's major shareholders? Myomo's stock is owned by many different retail and institutional investors. Top institutional shareholders include Rosalind Advisors Inc. (8.59%), Herr Investment Group LLC (5.71%), Vanguard Group Inc. (4.05%), Essex Investment Management Co. LLC (2.09%), PFG Advisors (0.16%) and Accel Wealth Management (0.15%). Insiders that own company stock include David A Henry, Harry Kovelman, Micah Mitchell, Milton Mayo Morris, Paul R Gudonis, Thomas Aloysius Jr Crowley and Thomas F Kirk. View institutional ownership trends. How do I buy shares of Myomo? Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:MYO) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myomo, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.